| 产品描述: | PKUMDL-WQ-2201 is a PHGDH non-NAD+-competing allosteric inhibitor (IC50=35.7 μM). PKUMDL-WQ-2201 also inhibits PHGDH mutants with IC50s of 69 μM (T59A) and >300 μM (T56AK57A), respectively. PKUMDL-WQ-2201 inhibits de novo serine synthesis in cancer cells, and reduces tumor growth[1][2]. |
| 体外研究: |
PKUMDL-WQ-2201 (5-20 mg/kg; 腹腔注射; 每天 1 次, 共 30 天) 与对照组小鼠相比,对 MDA-MB-468 异种移植有显著的抑制作用,但不影响肿瘤生长[1]。 |
| 体内研究: |
PKUMDL-WQ-2201 (10 nM-100 μM; 3 d) 对 PHGDH 扩增的乳腺癌细胞系具有良好的选择性和抑制作用,EC50 值分别为 7.7 μM (MDA-MB-468) 和 10.8 μM (HCC70)[1]。 |
| 参考文献: |
1. Wang Q, et al. Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity. Cell Chem Biol. 2017 Jan 19;24(1):55-65. 2. Zhao JY, et al. A retrospective overview of PHGDH and its inhibitors for regulating cancer metabolism. Eur J Med Chem. 2021 May 5;217:113379. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.842 ml |
14.212 ml |
28.424 ml |
| 5 mM |
0.568 ml |
2.842 ml |
5.685 ml |
| 10 mM |
0.284 ml |
1.421 ml |
2.842 ml |
| 50 mM |
0.057 ml |
0.284 ml |
0.568 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |